Fact CheckerSign in

NCT05255978Recruiting

A Prospective/Retrospective, Observational Follow-up Study of Chronic Hepatitis B With Non-alcoholic Fatty Liver Disease.

Source: ClinicalTrials.gov · Last updated 25 Feb 2022 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

This is a prospective/retrospective, observational follow-up study of effects of fatty liver on chronic hepatitis B. Patients will join this study who undergo transient elastography with liver stiffness (LS) and CAP measurements or Ultrasonic examination. All recruited subjects will undergo comprehensive clinical, anthropometric and laboratory assessments at the time when transient elastography or Ultrasonic examination is performed. We plan to compare the relationship between chronic hepatitis B and non-alcoholic fatty liver disease. Patients will be divided into several groups based on the demand.

Status (registry)
Recruiting
Study type
Observational
Enrollment
10000 (estimated)
First submitted
16 Feb 2022
Start date
24 Feb 2022
Primary completion date
24 Jun 2023
Lead sponsor
Qin Ning
NCT number
NCT05255978

What you commit to

  • Study type: Observational
  • Planned participants: 10000
  • From 24 Feb 2022 to the primary completion date, 24 Jun 2023
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • \-

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Department and Institute of Infectious Disease
Coordinator of this site? Confirm its status
WuhanChinaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.